Last updated 9 days ago

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 patients around the world
Available in Brazil, United States
The primary endpoint of interest in this study is time to next treatment (TTNT), a measure that will determine how long T-DXd allows patients to derive clinical benefit from the study drug.
Daiichi Sankyo
9Research sites
250Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Erasto Gaertner
Recruiting
Rua Joaquim Amaral - Cajuru, Curitiba - PR, 81520, Brazil
Centro Pesquisas Oncologicas - CEPON
Recruiting
655 Rio Itacorubi Florianópolis SC BR 88034-000, Rod. Admar Gonzaga - Itacorubi, Florianópolis - SC
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Recruiting
Ijui, 98700-000
Centro de Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
Recruiting
Jau, 17210080
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Recruiting
Campus Universitário S/N, Bloco G Subsolo II, Monte Alegre, Ribeirão Preto, Sao Paulo
Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO
Recruiting
Av. Príncipe de Gales, 821 - Vila Principe de Gales, Santo André - SP, 09060-650
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
Av. Brg. Faria Lima, 5544 Sao Jose do Rio Preto - Estado de São Paulo 15090-000
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Recruiting
Av. Dr. Arnaldo, 251 - Consolação, São Paulo - SP, 01255-090, Brazil
Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária
Recruiting
733 Avenida Brigadeiro Luís Antônio São Paulo, SP 01317-001
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy